Biotech Investment Analyst — Drug Asset & Company Assessment
$120–$200/hrRemote — US-based or deep US-market experienceContract
Apply now →You'll finish your application on Mercor, our hiring partner: sign up and take their short AI interview.
Mercor is partnering with a biotech and pharma research team on expert human-evaluation work — creating and critiquing rubrics that analyze commercial drugs and drug-development programs. We're seeking a biotech investment analyst (specialist-fund background) for a paid pilot, with the potential to continue as the work scales.
Responsibilities
Create and critique rubrics that analyze commercial drugs and drug-development programs
Provide overall company and asset assessment — mechanism, clinical data, competitive position, and value drivers
Judge the quality of an investment-style thesis and flag weak, overconfident, or missing assumptions
Apply your assessment across the pilot's set of companies (~5–10)
Requirements
US-based biotech / healthcare investment analyst with a specialist-fund background
Familiarity with biotech/pharma development programs
Able to assess a drug asset and the company behind it end-to-end
5+ years evaluating biotech/pharma companies or assets
Engagement Details
Duration: Approximately 10–20 hours over a 1–2 week pilot
Remote — US-based
Why Participate
Help improve expert AI evaluation of drugs and drug-development programs
Recurring engagement for strong contributors